Pressure-Enabled Drug Delivery (PEDD) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a murine pancreatic cancer model-Reference-Cited by-同舟云学术

Pressure-Enabled Drug Delivery (PEDD) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a murine pancreatic cancer model

Published:2023-09 Issue:3 Volume:174 Page:666-673
ISSN:0039-6060
Container-title:Surgery
language:en
Short-container-title:Surgery

Author:

Capacio Benedict A.,Shankara Narayanan Jayanth S.,Vicente Diego A.^ORCID,Liu Yujia,LaPorte Jason P.,Cox Bryan F.,Jaroch David B.,Katz Steven C.,White Rebekah R.^ORCID

Publisher

Elsevier BV

Subject

Surgery

Reference35 articles.

1. Estimated projection of US cancer incidence and death to 2040;Rahib;JAMA Netw Open,2021

2. Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: current limitations and future options;Kabacaoglu;Front Immunol,2018

3. Myeloid-derived suppressor cells in the tumor microenvironment;Dysthe;Adv Exp Med Biol,2020

4. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression;Serafini;Semin Cancer Biol,2006

5. Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship;Monu;Immunol Invest,2012

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastases;Journal for ImmunoTherapy of Cancer;2024-07

2. DNA sensing of dendritic cells in cancer immunotherapy;Frontiers in Molecular Biosciences;2024-05-22